SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM Review

  


Authors: Jurgens, E.; Usmani, S. Z.
Review Title: SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM
Abstract: The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last 2 decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive. Recent, novel immunotherapies including chimeric antigen T-cell (CAR-T) therapy have demonstrated deep and durable responses in relapsed and refractory multiple myeloma (RRMM). Currently 2 CAR-T products, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), are approved by the FDA for the treatment of RRMM. The success of CAR-T therapy revolutionized the management of RRMM prompting clinical trials studying CAR-T therapy in the first line setting. The ongoing KarMMa-4, CARTITUDE-5, and CARTITUDE-6 clinical trials may establish CAR-T therapy as a first line option potentially supplanting ASCT in the initial treatment of NDMM. In this review, we discuss the current standard of care management of NDMM, trace the evolution of CAR-T clinical trials in RRMM, and survey ongoing clinical trials studying CAR-T therapy in NDMM. © 2024 Elsevier Inc.
Keywords: multiple myeloma; minimal residual disease; relapsed; chimeric antigen receptors; newly diagnosed
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 24
Issue: 5
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2024-05-01
Start Page: 277
End Page: 284
Language: English
DOI: 10.1016/j.clml.2024.01.001
PUBMED: 38331676
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184597138&doi=10.1016%2fj.clml.2024.01.001&partnerID=40&md5=a1d79ea4169b916b2d248095c478ceb9
Notes: Review -- MSK corresponding author is Saad Usmani -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    297 Usmani
  2. Eric Jurgens
    14 Jurgens
Related MSK Work